GlassScriptPhysician profile
Jessica Cano
NPI 1811761422
$1,270.49
in general payments reported to CMS, 2019-2025
18 companies · $982 in 2025
The $982 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $21.86 · 2024: $267 · 2025: $982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,248.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $358.47 | 2025 | Jardiance |
| Antares Pharma, INC. | $125.76 | 2025 | Xyosted |
| Lilly USA, LLC | $125.01 | 2025 | Mounjaro, Zepbound |
| Amarin Pharma, INC. | $124.92 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $91.02 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $79.80 | 2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $77.25 | 2024 | Otezla, Repatha |
| Astellas Pharma US INC | $49.77 | 2025 | Veozah |
| Exact Sciences Corporation | $45.84 | 2025 | Cologuard Collection Kit |
| Alkermes, INC. | $29.80 | 2025 | Vivitrol |
| Viiv Healthcare Company | $26.24 | 2024 | Apretude |
| Ardelyx, INC. | $23.71 | 2025 | Ibsrela |
| Dexcom, INC. | $22.05 | 2025 | Dexcom G6 Transmitter |
| Genzyme Corporation | $21.86 | 2022 | |
| Pfizer INC. | $21.01 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.31 | 2025 | Xifaxan |
| Phadia US INC. | $13.89 | 2025 | Immunocap |
| Abbvie INC. | $13.78 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Cano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.